



MELANOMA ^{15 YEARS} **2024**
BRIDGE

Naples (Italy)

December 5th-7th, 2024


Royal Continental Hotel

GENERAL INFORMATION

CONGRESS VENUE

Royal Continental Hotel

Via Partenope, 38 - 80121 Naples



REGISTRATION

Registration fee: €800.00 + 22% VAT

For information, registration, and payments, please contact:

registration@melanomabridge.org

Confirmation of registration will be sent by the organizing secretariat.

Only registered participants will be admitted to the event.

- » The registration fee includes:
- Participation in scientific sessions
 - Congress kit (badge, notepad, pen)
 - Coffee breaks and lunches

OFFICIAL LANGUAGE

The official language is English.

SCIENTIFIC RATIONAL

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immune-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune - and target - therapies has further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the "Great Debate" sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

SCIENTIFIC PROGRAM

DAY 1 Thursday, Dec 5th

OPENING CEREMONY**

Chairpersons: **Paolo A. Ascierto, Franco Marincola**

6.20 pm Update in Pathology

Janis Taube

6.40 pm Update in Melanoma research

Omid Hamid

7.00 pm Melanoma research funding opportunities

Marc Hurlbert

7.10 pm Through the Keyhole: The Next Wave of Therapies for Patients with Uveal Melanoma,

Kevin O'Neill and Marlana Orloff

7.25 pm Patient Advocacy reloaded. How to help patient empowerment in the new Melanoma era

Samantha Guild and Claudia Piazza Cidonio

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 2 Friday, Dec 6th

9.20 am Introduction and objectives
Paolo A. Ascierto

SESSION 1

MORE TRANSLATIONAL RESEARCH IN MELANOMA

Chairpersons: **Magdalena Thurin, Lisa Villabona**

9.30 am What should you do with pathologic non-responders for neoadjuvant therapy?
Christian Blank

9.45 am What do we know about how much neoadjuvant treatment to give?
Michael Postow

10.00 am The an-unanswered questions in melanoma
Iman Osman

10.15 am The latest omics tools for translational research questions
Mitch Levesque

10.30 am Prognostic effects of combined clinicopathological factors and tumor mutation burden - an InterMEL study of Stage II/III primary cutaneous
Marc S. Ernstoff

10.45 am **DISCUSSION Round Table**

11.15 am **Coffee Break****

11.30 am CME SYMPOSIUM

Neoadjuvant treatment in melanoma: an update

Christian Blank*

The status of art of adjuvant therapy in melanoma

Paolo A. Ascierto

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori**

12.20 am Genetically modified cells therapy VS unmodified cells therapy
Chrystal Paulos vs Allison Betof Warner

12.45 am Are IrAE associated with better outcomes? Yes or no
Ryan Sullivan vs Olivier Michielin

1.10 pm **Lunch****

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 2 Friday, Dec 6th

SESSION 2

MELANOMA TUMOR BIOLOGY

Chairperson: **Paul Nathan***

2.00 pm Cancer Stem Cells and Lineage Plasticity as Immuno-therapeutic targets
Dean Tang

2.15 pm Melanoma biology in the context of clinical and experimental resistance
Roger Lo

2.30 pm New immunotherapy strategies based on understanding resistance
Thomas Gajewski

2.45 pm Improving mRNA vaccine in melanoma
Michelle Krogsgaard

3.00 pm The genetic and transcriptomic peripheral biomarkers of efficacy and toxicity to melanoma immune checkpoint inhibition
Tomas Kirchoff

3.15 pm Designing tumor-selective therapeutic strategies for RAS pathway-driven cancers
Poulikos Poulikakos

3.30 pm **DISCUSSION Round Table**

4.00 pm **SYMPOSIUM**

The new era of target therapy in metastatic melanoma
Paolo A. Ascierto, Reinhard Dummer

4.50 pm **SHORT SYMPOSIUM**

Current treatment of metastatic uveal melanoma and future perspectives
Jessica C. Hassel

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**

5.20 pm Overview

Artificial intelligence-driven diagnosis of melanoma and melanoma skin cancers
Titus Brinker

Debates

5.35 pm Artificial intelligence VS human dermatology
TBD vs Laura Ferris

6.00 pm Artificial intelligence VS human pathology
Carlo Bifulco vs Janis Taube

6.25 pm Artificial intelligence VS RWE
Giuseppe Masucci vs Dirk Schadendorf

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 3 Saturday, Dec 7th

9.15 am **Welcome Coffee****

SESSION 3

EMERGENT STRATEGIES

Chairpersons: **Mario Mandalà, Giuseppe Palmieri**

9.30 am Multiomic predictive markers for primary stage II & III melanoma patients
Nancy Thomas

9.45 am Lineage plasticity and relationship to TME
David Goodrich

10.00 am Where will neoadjuvant make the difference and replace adjuvant and where will standard (GEP/algorithm) test on primary melanoma clean up adjuvant therapy
Alexander M.M. Eggermont

10.15 am Emergent strategies and frontiers in cancer staging and classification: melanoma as a paradigm
Jeffrey Gershenwald

10.30 am AI strategies for digital pathology- based predictive biomarkers
Olivier Michielin

10.45 am Checkpoint Inhibitors 2.0
James Smithy

11.00 am What is next for tumor infiltrating lymphocyte therapy after the FDA approval
Allison Betof Warner

11.15 am **DISCUSSION Round Table**

11.40 am **Coffee break****

SESSION 4

MELANOMA BRAIN METASTASES

Chairpersons: **Hussein Tawbi, Kim Margolin**

11.55 am Preclinical research
Tullia Bruno

12.10 pm Tissue based analyses and immune competent in vivo models
Tim Heffernan

12.25 pm On the edge of clinical and translational
Reinhard Dummer

12.40 pm **DISCUSSION Round Table**

1.00 pm **Lunch****

**Invited Speakers*

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DAY 3 Saturday, Dec 7th

2.00 pm **SYMPOSIUM**
New approaches and treatments for advanced melanoma
Paolo A. Ascierto, Hussein Tawbi

2.50 pm **SYMPOSIUM**
Ignite change within cancer vaccines development
Omid Hamid, Igor Puzanov

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**

3.40 pm Steroids vs alternative strategies for toxicity management
Ryan Sullivan vs Douglas Johnson

4.30 pm Wich is the best combination therapy? NIVO/RELA VS IPI/NIVO
Janice Mehnert vs Hussein Tawbi

4.55 pm PD-1 refractory melanoma: BRAF MEK VS IPI/NIVO
Jeffrey Sosman vs Den Olson

5.20 pm Putting it all together: Practical Considerations for Monday Clinic
Sanjiv S. Agarwala

5.35 pm **Conclusions**

**Invited Speakers*

*** Not included in the CME accredited program*

PRESIDENCY



Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy



Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy



Iman Osman

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US



Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy

Carlo Bifulco

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Christian Blank

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

SCIENTIFIC BOARD

Elizabeth M. Burton

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield

Adjunct Professor of Microbiology and Immunology, University of California San Francisco, CA, US

Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

Mary Dean

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

Sandra Demaria

Professor of Radiation Oncology, Professor of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY, US

Reinhard Dummer

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Alexander M.M. Eggermont

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical & Translational Immunotherapy, Utrecht University, Utrecht, Netherlands

Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Jeffrey E. Gershenwald

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

Omid Hamid

Chief of Research/Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

SCIENTIFIC BOARD

Samir N. Khleif

Director of Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

Giuseppe Masucci

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

Iman Osman

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Dirk Schadendorf

Director of the Department of Dermatology, University Hospital Essen, Essen, Germany

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

CONTINUING MEDICAL EDUCATION

CME Provider

T&C srl - Provider No. 13

Via Giotto 3, 20145 Milan, Italy

E-mail: raffaella.ottoboni@tccompany.it

CME Credits

CME Code: 13 - 431681 Ed.1

The course has been accredited with 4.5 CME credits.

The regulations for the acquisition of CME credits are available on the website: www.tccompany.it.

To obtain CME credits, participants must attend at least 90% of the total course duration and complete the event evaluation.

National Objective:

Technical and professional content (knowledge and skills) specific to each profession, specialization, and ultra specialized activity, including rare diseases and gender medicine.

Target Audience:

This course is intended at 250 participants among the following professions:

- Pharmacists
- Biologists
- Medical Doctors specializing in:
Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Gastroenterology, Respiratory diseases, Internal Medicine, Nephrology, Neurology, Oncology, Radiotherapy, General Surgery, Plastic and Reconstructive Surgery, Gynecology and Obstetrics, Urology, Pathological Anatomy, Clinical Pharmacology and Toxicology, Medical Genetics Laboratory, Nuclear Medicine, Clinical Pathology (Chemical-Clinical Laboratory and Microbiology), Radio diagnostics, Hygiene, Epidemiology, and Public Health, General Medicine (General Practitioners), Nutrition Science and Dietetics, Palliative Care
- Pediatric Nurses
- Nurses

CME PROVIDER

T&C Srl

Via Giotto 3, 20145 Milan, Italy

Cell. 334/1837054

www.tccompany.it



ORGANIZING SECRETARIAT

Vivenko Srl Società Benefit

Via De Amicis 42, 20123 Milan, Italy

www.vivenko.net

info@melanomabridge.org

